Our Drug Candidates


BP001 is an antibiotic and wound healing agent for infected eye wounds. BP001 is in the preclinical stage, with an Investigational New Drug application anticipated to be filed with the Food and Drug Administration in early 2018.


BP002 is a therapeutic treatment for cystic fibrosis and hospital acquired pneumonia. We are continuing studies to enable an IND filing.